Drug intelligence / Profile preview

guanosine

Development stage
Preclinical
Modality
Small Molecules
Administration
Intraperitoneal
01

Overview

Guanosine is a purine nucleoside composed of the base guanine attached to a ribose (ribofuranose) ring via a β-N9-glycosidic bond. It is an endogenous molecule that can be phosphorylated to form GMP, cGMP, GDP, and GTP—key intermediates in signal transduction pathways and essential for nucleic acid synthesis, protein synthesis, photosynthesis (in plants), muscle contraction, and intracellular signaling. In biological systems, it plays roles in RNA splicing reactions and as a precursor for several antiviral drugs. Experimentally and preclinically, exogenous administration of guanosine has shown neuroprotective effects in models of central nervous system diseases such as ischemic stroke, Alzheimer's disease, Parkinson's disease, spinal cord injury, nociception (pain), and depression. Its neurobiological actions are thought to involve activation of intracellular signaling pathways and interaction with the adenosinergic system[1][2][3].

Other names
2-amino-1,9-dihydro-9-β-D-ribofuranosyl-6H-purin-6-one2(3H)-imino-9-β-D-ribofuranosyl-9H-purin-6(1H)-one9-β-D-ribofuranosylguanineguanine ribosideguanine-9-beta-D-ribofuranosideguanine9-beta-D-ribofuranosideguanine 9-beta-D-ribofuranosideguanosinguanosinavernineGuanozin
02

Targets

ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)

Beyond the preview

Go deeper on guanosine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on guanosine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call